Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is roughly 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the very first quarter of 2021.

The present consensus among eleven TipRanks analysts is for a moderate Buy rating of shares in CVS Health, with an average price goal of $84.

The analysts priced targets range from a high of $101 to a low of sixty one dolars.

From its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The retail or Long Term Care segment includes selling of prescription drugs as well as assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products as well as similar services, which includes medical, pharmacy, dental, behavioural health, healthcare control capabilities. The Corporate segment involves in offering management as well as administrative services. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *